Table 2. Characteristics at antiretroviral therapy initiation in 80 843 patients across seven programmes in Kenya, Uganda and Tanzania.
| Baseline characteristics | Overall n = 80 843 | Kenya 2 programmes n = 61 109 | Uganda 3 programmes n = 17 793 | Tanzania 2 programmes n = 1941 |
|---|---|---|---|---|
| Female, n (%)a | 52 158 (64.5) | 39 299 (64.3) | 10 978 (61.6) | 1251 (64.5) |
| Age in years, median (IQR) | 36 (30–43) | 36 (30–43) | 35 (29–41) | 38 (32–45) |
| BMI (kg/m2), median (IQR) | 20.1 (17.9–22.5) | 19.9 (17.9–22.3) | 20.8 (18.5–23.4) | 21.5 (21.2–23.8) |
| Hemoglobin level (g/dl); median (IQR) | 11.3 (9.7–12.9) | 11.2 (9.6–12.8) | 11.7 (10.2–13.1) | 9.6 (7.9–11.4) |
| CD4+ cell count (cells/μl), median (IQR) | 126 (52–202) | 130 (56–208) | 111 (39–187) | 113 (44–188) |
| Prior ART use for PMTCT | b299/50 277 (0.6) | 219/39 299 (0.6) | 80/10 978 (0.7) | n/a |
| First-line ART regimen | ||||
| NNRTI-based regimenc; n (%) | d78 106 (96.6) | 58 833 (96.3) | 17 332 (97.4) | 1941 (100) |
| PI-based regimen | 2051 (2.5) | 1770 (2.9) | 281 (1.6) | |
| Triple NRTI | 322 (0.4) | 147 (0.2) | 175 (0.98) | |
| Otherse | 364 (0.5) | 359 (0.6) | 5 (0.03) |
Sites in Kenya were Academic Model Providing Access to Healthcare (AMPATH) and Family AIDS Care and Education Services (FACES) sites, Uganda sites were Mbarara Immune Suppression Syndrome Clinic, Masaka Regional Hospital HIV Clinic and Infectious Diseases Institute, Makerere University, and Tanzania sites were Ocean Road Cancer Institute (ORCI) and Tumbi Special Hospital. ART, antiretroviral therapy; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PMTCT, prevention of mother to child transmission.
13 missing gender.
1881 women had missing data on prior ART use for PMTCT.
NNRTI-based regimen included all efavienz [16 888 (21.6%)] and nevirapine-containing regimens [61 622 (78.9%)]. All patients initiated zidovudine/stavudine containing regimen that were recommended and available at the time.
404 had three-drug regimen with both nevirapine and efavirenz.
Others includes individuals with ART regimen containing more than active antiretroviral drugs (excluding those with boosted lopinavir).